Abstract
Background: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a highly effective treatment for relapsed or refractory multiple myeloma (MM). However, manufacturing CAR T cells can take 3 to 4 weeks, leaving patients vulnerable to disease progression during this waiting period. Bridging therapy aims to address this gap by controlling disease and improving CAR T-cell efficacy. Objectives:This review summarizes the role of bridging therapy in CAR T-cell therapy for MM, focusing on the rationale and goals of bridging therapy, timing of initiation, infection risk management, selection of bridging regimens, and clinical implications, including patient education and communication. This review summarizes the role of bridging therapy in CAR T-cell therapy for MM, focusing on the rationale and goals of bridging therapy, timing of initiation, infection risk management, selection of bridging regimens, and clinical implications, including patient education and communication. Methods: Relevant literature on CAR T-cell therapy and bridging therapy in MM was reviewed, including clinical trials and real-world data. Findings: Bridging therapy may be crucial for some patients, particularly for those with rapidly progressive disease. The optimal timing for initiating bridging therapy remains under investigation, but it can begin as soon as leukapheresis is completed. Prophylactic antibiotics or antivirals and close monitoring are essential for preventing infections during this period. The choice of bridging regimen depends on individual patient characteristics and prior therapies. Effective patient education and communication between local oncology teams and CAR T-cell centers are critical. Implications: Bridging therapy plays a vital role in optimizing CAR T-cell therapy outcomes for MM patients. Further research is needed to define the optimal use of bridging therapy in this evolving treatment landscape.
References
Ababneh, H. S., Yee, A. J., Raje, N. S., Martin, S., Frigault, M. J., Ng, A. K., & Patel, C. G. (2023). Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. Radiotherapy and Oncology, 189, 109933. https://doi.org/10.1016/j.radonc.2023.109933
Afrough, A., Hashmi, H., Hansen, D. K., Sidana, S., Ahn, C., Dima, D., Freeman, C. L., Castaneda Puglianini, O. A., Kocoglu, M. H., Atrash, S., Voorhees, P. M., Shune, L., Simmons, G., Sborov, D. W., Ferreri, C. J., Wagner, C. B., Patel, K. K., Khouri, J., Anderson, L. D., Jr., & Lin, Y. (2023). Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium. Journal of Clinical Oncology, 41(16_suppl), Abstract 8013. https://doi.org/10.1200/JCO.2023.41.16_suppl.8013
Ailawadhi, S., Shune, L., Wong, S. W., Lin, Y., Patel, K., & Jagannath, S. (2024). Optimizing the CAR T-cell therapy experience in multiple myeloma: Clinical pearls from an expert roundtable. Clinical lymphoma, myeloma & leukemia, 24(5), e217–e225. https://doi.org/10.1016/j.clml.2024.01.014
Anderson, L. D., Jr, Dhakal, B., Jain, T., Oluwole, O. O., Shah, G. L., Sidana, S., Perales, M. A., & Pasquini, M. C. (2024). Chimeric antigen receptor T cell therapy for myeloma: Where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and cellular therapy, 30(1), 17–37. https://doi.org/10.1016/j.jtct.2023.10.022
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O’Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T. M., Allred, A. J., Olyslager, Y., Banerjee, A.,…Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. Lancet (London, England), 398(10297), 314–324. https://doi.org/10.1016/S0140-6736(21)00933-8
Bhaskar, S. T., Dholaria, B. R., Sengsayadeth, S. M., Savani, B. N., & Oluwole, O. O. (2021). Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem, 3(Suppl 1), 39–45. https://doi.org/10.1002/jha2.335
Bristol-Myers Squibb. (2021). Abecma (idecabtagene vicleucel) package insert. https://packageinserts.bms.com/pi/pi_abecma.pdf
Bristol-Myers Squibb. (2023). Abecma (idecabtagene vicleucel) package insert. https://packageinserts.bms.com/pi/pi_abecma.pdf
Cohen, A. (2022). CAR T-cell therapy in myeloma: Myeloma Today in conversation with Adam D. Cohen, MD. Myeloma Today, 22(4), 7. https://www.myeloma.org/resource-library/myeloma-today-fall-2022
Cohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M. V., Lendvai, N., Jackson, C. C., De Braganca, K. C., Schecter, J. M., Marquez, L., Lee, E., Cornax, I., Zudaire, E., Li, C., Olyslager, Y., Madduri, D., Varsos, H., Pacaud, L.,…Jagannath, S. (2022). Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 12(2), 32. https://doi.org/10.1038/s41408-022-00629-1
Connelly-Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., Witt, V., Zantek, N. D., & Dunbar, N. M. (2023). Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis, 38(2), 77–278. https://doi.org/10.1002/jca.22043
Fandrei, D., Seiffert, S., Rade, M., Rieprecht, S., Gagelmann, N., Born, P., Wiemers, T., Weidner, H., Kreuz, M., Schassberger, T., Koßmann, J., Mangold, M., Fürst, D., Fischer, L., Baber, R., Heyn, S., Wang, S. Y., Bach, E., Hoffmann, S., Metzeler, K. H.,…Merz, M. (2025). Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma. Blood Cancer Discovery, 6(1), 38–54. https://doi.org/10.1158/2643-3230.BCD-24-0118
Ferreri, C. J., Hildebrandt, M. A. T., Hashmi, H., Shune, L. O., McGuirk, J. P., Sborov, D. W., Wagner, C. B., Kocoglu, M. H., Rapoport, A., Atrash, S., Voorhees, P. M., Khouri, J., Dima, D., Afrough, A., Kaur, G., Anderson, L. D., Jr, Simmons, G., Davis, J. A., Kalariya, N., Peres, L. C.,…Castaneda Puglianini, O. A. (2023). Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer Journal, 13(1), 117. https://doi.org/10.1038/s41408-023-00886-8
Gagelmann, N., Dima, D., Merz, M., Hashmi, H., Ahmed, N., Tovar, N., Oliver-Caldés, A., Stölzel, F., Rathje, K., Fischer, L., Born, P., Schäfer, L., Albici, A.-M., Schub, N., Kfir-Erenfeld, S., Assayag, M., Asherie, N., Wulf, G. G., Kharboutli, S.,…& Fernández de Larrea, C. (2024). Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma. Journal of Clinical Oncology, 42(14), 1554–1564. https://doi.org/10.1200/JCO.23.02232
Geethakumari, P. R., Ramasamy, D. P., Dholaria, B., Berdeja, J., & Kansagra, A. (2021). Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments. Current Hematologic Malignancy Reports, 16(4), 345–356. https://doi.org/10.1007/s11899-021-00635-3
Hoffmann, M. S., Hunter, B. D., Cobb, P. W., Varela, J. C., & Munoz, J. (2023). Overcoming barriers to referral for chimeric antigen receptor t cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma. Transplantation and Cellular Therapy, 29(7), 440–448. https://doi.org/10.1016/j.jtct.2023.04.003
Hungria, V., Piérola, A. A., Filho, J. S., Crusoe, E., Filho, R. J. P. M., Maiolino, A., & Rodríguez-Otero, P. (2023). CAR-T cell therapy for multiple myeloma: A practical toolkit for treatment in Brazil. Hematology, Transfusion and Cell Therapy, 45(2), 266–274. https://doi.org/10.1016/j.htct.2022.08.002
Janssen. (2023). Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma. June 6. https://www.jnj.com/media-center/press-releases/janssen-submits-supplemental-biologics-license-application-to-u-s-fda-seeking-approval-of-carvykti-for-the-earlier-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma
Joseph, N. S., Kaufman, J. L., Dhodapkar, M. V., Hofmeister, C. C., Almaula, D. K., Heffner, L. T., Gupta, V. A., Boise, L. H., Lonial, S., & Nooka, A. K. (2020). Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. Journal of Clinical Oncology, 38(17), 1928–1937. https://doi.org/10.1200/JCO.19.02515
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2016). Global manufacturing of CAR T cell therapy. Molecular Therapy. Methods & Clinical Development, 4, 92–101. https://doi.org/10.1016/j.omtm.2016.12.006
Lin, Y., Qiu, L., Usmani, S., Joo, C. W., Costa, L., Derman, B., Du, J., Einsele, H., Fernandez de Larrea, C., Hajek, R., Ho, P. J., Kastritis, E., Martinez-Lopez, J., Mateos, M. V., Mikhael, J., Moreau, P., Nagarajan, C., Nooka, A., O’Dwyer, M., Schjesvold, F.,…International Myeloma Working Group. (2024). Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. The Lancet. Oncology, 25(8), e374–e387. https://doi.org/10.1016/S1470-2045(24)00094-9
Manjunath, S. H., Cohen, A. D., Lacey, S. F., Davis, M. M., Garfall, A. L., Melenhorst, J. J., Maxwell, R., Arscott, W. T., Maity, A., Jones, J. A., Plastaras, J. P., Stadtmauer, E. A., Levine, B. L., June, C. H., Milone, M. C., & Paydar, I. (2021). The safety of bridging radiation with Anti-BCMA CAR T-cell therapy for multiple myeloma. Clinical Cancer Research, 27(23), 6580–6590. https://doi.org/10.1158/1078-0432.CCR-21-0308
Meir, J., Abid, M. A., & Abid, M. B. (2021). State of the CAR-T: Risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses. Transplantation and Cellular Therapy, 27(12), 973–987. https://doi.org/10.1016/j.jtct.2021.09.016
Munshi, N. C., Anderson, L. D., Jr, Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., Petrocca, F.,…San-Miguel, J. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. The New England Journal of Medicine, 384(8), 705–716. https://doi.org/10.1056/NEJMoa2024850
Parikh, R. H., & Lonial, S. (2023). Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA, 73(3), 275–285. https://doi.org/10.3322/caac.21771
Pessach, I., & Nagler, A. (2023). Leukapheresis for CAR-T cell production and therapy. Transfusion and Apheresis Science, 62(6), 103828. https://doi.org/10.1016/j.transci.2023.103828
Piñeyroa, J. A., Cid, J., & Lozano, M. (2022). Get off on the right foot: how to plan an efficient leukocytapheresis to collect T cells for CAR T-cell manufacturing. Transfusion Medicine and Hemotherapy, 50(2), 98–104. https://doi.org/10.1159/000528331
Qayed, M., McGuirk, J. P., Myers, G. D., Parameswaran, V., Waller, E. K., Holman, P., Rodrigues, M., Clough, L. F., & Willert, J. (2022). Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy, 24(9), 869–878. https://doi.org/10.1016/j.jcyt.2022.05.003
Rajkumar S. V. (2022). Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology, 97(8), 1086–1107. https://doi.org/10.1002/ajh.26590
Richter, J. (2024). Like a bridge over troubled water: Keeping the myeloma down en route to CAR-T. Blood Cancer Journal, 14(64), https://doi.org/10.1038/s41408-024-01049-z
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M. V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., Costa, L. J.,…Einsele, H. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. The New England journal of medicine, 389(4), 335–347. https://doi.org/10.1056/NEJMoa2303379
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025). Cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75(1), 10–45. https://doi.org/10.3322/caac.21871
Wada, F., Jo, T., Arai, Y., Kitawaki, T., Mizumoto, C., Kanda, J., Nishikori, M., Yamishita, K., Nagao, M.,…Takaori-Kondo, A. (2022). T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR T-cell therapy. Scientific Reports, 12(1), 18696. https://doi.org/10.1038/s41598-022-23589-9
Zafar, A., Huang, C. Y., Lo, M., Arora, S., Chung, A., Wong, S. W., Wolf, J., Martin, T. G., Shah, N., & Banerjee, R. (2023). Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma. Transplantation and Cellular Therapy, 29(8), 504.e1–504.e7. https://doi.org/10.1016/j.jtct.2023.05.016
Zhang, X., Zhang, H., Lan, H., Wu, J., & Xiao, Y. (2023). CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Frontiers in Immunology, 14, 1101495. https://doi.org/10.3389/fimmu.2023.1101495
